articleTop 1% cited

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

New England Journal of Medicine · 2013 · Vol. 369(18) · pp. 1691–1703

Daniel D. Von Hoff✉(Translational Genomics Research Institute)Thomas J. Ervin(Florida Cancer Specialists & Research Institute)Francis P. ArenaE. Gabriela Chiorean(Seattle University)Jeffrey R. Infante(Sarah Cannon)Malcolm J. Moore(Princess Margaret Hospital)Thomas E. SeaySergei Tjulandin(Russian Cancer Research Center NN Blokhin)Wen Wee(Roswell Park Comprehensive Cancer Center)Mansoor N. Saleh(Georgia Cancer Specialists)Marion Harris(Centro Oncológico de Galicia)Michele Reni(Mylan (Switzerland))Scot DowdenDaniel A. Laheru(Sidney Kimmel Comprehensive Cancer Center)Nathan Bahary(University of Pittsburgh Medical Center)Ramesh K. Ramanathan(Translational Genomics Research Institute)Josep Tabernero(Universitat Autònoma de Barcelona)Manuel Hidalgo(Centro Oncológico de Galicia)David Goldstein(Prince of Wales Hospital)Eric Van Cutsem(KU Leuven)Xinyu WeiJosé Iglesias(Bionomics (Australia))Markus F. Renschler

View via DOI Publisher page

Abstract

In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased. (Funded by Celgene; ClinicalTrials.gov number, NCT00844649.).

Pancreatic and Hepatic Oncology Research Neuroendocrine Tumor Research Advances Renal cell carcinoma treatmentGemcitabineMedicineInternal medicinePancreatic cancerHazard ratioPaclitaxelDeoxycytidineOncologyClinical endpointChemotherapy

MeSH terms

GemcitabineAdenocarcinomaAdultAgedAged, 80 and overAlbuminsAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineFemaleHumansMaleMiddle AgedNervous System DiseasesNeutropenia

Citations

6,561

FWCI

176.66

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States